Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI360 Monotherapy or Combination in Advanced Solid Tumors
NCT05043298Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI-360 in solid tumor (advanced stage), pancreatic carcinoma and gastric adenocarcinoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Safety and tolerance and Recommended Phase 2 Dose. Started Oct 2021; status: completed.
02
Drugs
IBI-360
03
Conditions
solid tumor (advanced stage)pancreatic carcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT05043298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043298.